Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of V920 Ebola Vaccine in Healthy Adults Ensayo clínico de fase III, aleatorizado y controlado con placebo para evaluar la seguridad y la capacidad inmunógena de la vacuna contra el virus del Ébola V920) en adultos sanos
1-To determine whether vaccination with V920 from three separate consistency lots results in equivalent immunogenicity. 2- To determine the safety and tolerability of V920 from three Consistency Lot g...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia- Study B
All Main/Primary objectives are MK-4305 high dose compared to placebo, as measured by change from baseline: Maintenance- 1. Mean subjective total sleep time (sTSTm) at Month 1 2. Wakefulness after p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A phase IIb study of ridaforolimus, dalotzumab and exemestane in combination in advanced breast cancer
The primary objective of the study is to evaluate the progression free survival (PFS) for the triplet combination of ridaforolimus, dalotuzumab and exemestane (R/D/E) compared to the combination of ri...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes between the age of 18 and 44 years old, who are not taking any medications
1. To assess the effect of treatment with MK-3102 compared with placebo on A1C. 2. To assess the safety and tolerability of MK-3102.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension
To study the effects of losartan compared to placebo (nonhypertensives) or amlodipine (hypertensives) on reduction of proteinuria in children and adolescents up to 17 years of age with hypertension (i...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes who are also receiving Glimepiride and Metformin
(1) After 24 weeks, to assess the effect of the addition of treatment with MK- 3102 compared with the addition of placebo on A1C. (2) To assess the safety and tolerability of MK 3102.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp
Update Il y a 4 ans
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis C Ensayo clínico para evaluar la combinación de MK 5172 y MK 8742 con ribavirina (RBV) en sujetos con hepatitis C
In treatment naïve (TN) non-cirrhotic subjects with chronic HCV infection with GT2, 4, 5 or 6: (1)Objective: To evaluate the efficacy of MK-5172 in combination with or without MK-8742 and/or RBV for ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Immunotherapeutic treatment with Pembrolizumab (antibody) in patients with early stage non-small cell lung cancer Tratamiento inmunoterápico con Pembrolizumab (anticuerpo) en pacientes en estadios iniciales de cáncer pulmonar no microcítico
To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (lobectomy/pneumonectomy) with or without standard adjuvant chemotherapy for stage IB (T ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A clinical trial to test if the drug ertugliflozin is safe and effective when compared to glimepiride in patients with Type 2 Diabetes whose sugar levels are not well controlled by treatment with metaformin
In subjects with T2DM and inadequate glycemic control on metformin: 1. After 52 weeks, to assess the A1C-lowering efficacy of the addition of ertugliflozin 15 mg q.d. compared with the addition of gl...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Pediatric Formulation Study
To evaluate the comparative bioavailability of a single-dose of the investigational oral pediatric minitablet formulation of MK-1439, 0.8 mg [100 mg total dose] compared to the adult formulation of MK...
Country
None
organs
None
Specialty
None
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next